ACRIVON THERAPEUTICS INC's ticker is and the CUSIP is 004890109. A total of 42 filers reported holding ACRIVON THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,000 | +200.0% | 1,116 | +301.4% | 0.00% | – |
| Q1 2024 | $2,000 | -83.3% | 278 | -88.8% | 0.00% | – |
| Q4 2023 | $12,000 | -20.0% | 2,488 | +59.4% | 0.00% | – |
| Q3 2023 | $15,000 | +25.0% | 1,561 | +72.1% | 0.00% | – |
| Q2 2023 | $12,000 | +50.0% | 907 | +36.4% | 0.00% | – |
| Q1 2023 | $8,000 | – | 665 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sands Capital Ventures, LLC | 1,652,605 | $21,417,761 | 6.34% |
| RA Capital Management | 4,810,508 | $62,344,184 | 1.18% |
| Perceptive Advisors | 3,007,858 | $38,981,840 | 1.13% |
| NEA Management Company, LLC | 481,677 | $6,242,534 | 0.48% |
| DAFNA Capital Management LLC | 76,852 | $996,002 | 0.27% |
| AAF Wealth Management, LLC | 10,678 | $138,387 | 0.09% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 100,000 | $1,296,000 | 0.03% |
| MARSHALL WACE, LLP | 597,469 | $7,743,198 | 0.02% |
| FEDERATED HERMES, INC. | 304,411 | $3,945,167 | 0.01% |
| Citadel Advisors | 1,649,646 | $21,379,412 | 0.00% |